YCYan Chen

Yan Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yan Chen has a total of 94 co-authors. Here are the top co-authors by number of shared publications:

  • Bei Xu

    Department of Clinical Laboratory, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China

    5 shared publications
  • Hongtao Xiao

    Department of Pharmacy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China

    5 shared publications
  • Xielin Feng

    4 shared publications
  • Dai-Long Fang

    State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China

    3 shared publications
  • Haiqing Wang

    Department of Hepatopancreatobiliary Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China

    3 shared publications
  • Jinliang Zhang

    Department of Hepatopancreatobiliary Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China

    3 shared publications

Latest Publications

  • Decoding cancer therapy resistance through advanced 3D organoid systems

    by Rui Ye, Jie Wang, Wan Xu, Yan Chen, Zhongwei Zhang, Yupei Zhang, Shugang Qin

    Precision oncology still faces low clinical translation rates. This is largely because two-dimensional (2D) culture systems cannot reproduce tumor heterogeneity and microenvironmental stress. Here, we review the applications of 3D cancer models, including scaffold-free spheroids, patient-derived organoids (PDOs) biobanks, and microphysiological systems (MPSs), in drug resistance modeling and personalized therapy. These platforms effectively model metabolic gradients, lineage plasticity, and immunological features within the tumor microenvironment (TME), thereby bridging the genotype-phenotype gap. They also capture physical immune exclusion, T cell exhaustion, and antigen presentation to facilitate the evaluation of immunotherapies. Last, we discuss key translational bottlenecks such as standardization and throughput, proposing the integration of advanced biomanufacturing, artificial intelligence (AI)–driven phenomics, and computational modeling to develop 3D cancer platforms into clinical predictive systems for optimizing precision treatment strategies.

  • Open Access

    Lenvatinib exposure is associated with therapeutic response in HCC, correlating with lipid metabolic reprogramming and spatial remodeling of the immune microenvironment

    by Haiqing Wang, Yichao Chen, Aixiang Liu, Yehan Zhou, Xuegang Yang, Peng Chen, Qian Jiang, Jinliang Zhang, Wentao Bo, Guimin Hou, et al.

    Background: Lenvatinib (LEN) is a standard first-line therapy for unresectable hepatocellular carcinoma (HCC), yet therapeutic outcomes are compromised by pharmacokinetic variability and resistance. The biological mechanisms linking sub-therapeutic exposure to metabolic and immune adaptations remain elusive. Methods: We conducted a prospective multi-omics study involving 194 HCC patients. Plasma drug concentrations were correlated with clinical outcomes. Resistance mechanisms were interrogated using untargeted plasma metabolomics, in vitro cell validation, exosomal miRNA sequencing, multiplex immunohistochemistry (mIHC), and single-cell RNA sequencing. Results: A C trough of 26.5 ng/mL was identified as the candidate threshold for predicting objective response rate. Furthermore, a combined model integrating this concentration threshold with tumor size demonstrated superior predictive performance across the training (AUC: 0.884), internal (AUC: 0.868), and external (AUC: 0.873) cohorts. Uric acid was the only clinical marker significantly correlated with LEN exposure ( r = 0.657, P < 0.001). Metabolomic profiling revealed that sub-therapeutic LEN exposure was characterized by distinct lipid metabolic reprogramming and the accumulation of acylcarnitines. Spatially, this sub-optimal exposure was associated with a “hot but suppressed” tumor microenvironment, characterized by high CD8 + T-cell and PD-L1 + densities, alongside the spatial colocalization and entrapment of T cells by CD163 + macrophages. The scRNA-seq further identified CD8 + T cells as the primary intercellular communication hub, linking metabolic shifts to spatial immune activation. Conclusion: Optimal LEN efficacy relies on maintaining plasma concentrations > 26.5 ng/mL. Sub-therapeutic exposure is closely associated with resistance, potentially involving specific lipid metabolic reprogramming and macrophage-mediated spatial exclusion of T cells. These findings advocate for therapeutic drug monitoring and combinatorial strategies targeting metabolic-immune axes.

  • Open Access

    Targeting the HIF-1α/PPARγ axis with curcumin carbon dots to combat uranium nephrotoxicity

    by Zhimin Jia, Chang Wang, Xiaowen Han, Jiawei Zeng, Chuandong He, Zhengguo Chen, Yan Chen, Bei Xu

    Uranium-induced nephrotoxicity involves complex mechanisms and lacks therapeutic interventions. This study identifies the HIF-1α/PPARγ axis as a key driver of renal lipid reprogramming and injury following uranium exposure. Using molecular docking, co-immunoprecipitation (Co-IP), ChIP-qPCR, and dual-luciferase reporter assays, we confirmed that HIF-1α directly regulates PPARγ expression and downstream lipotoxicity. The causal role of this axis was further validated using HIF-1α knockdown/knockout models and PPARγ pharmacological modulators (GW9662 and Rosi). Curcumin-derived carbon dots (CCDs) were synthesized at temperatures ranging from 120 to 210 °C. As-prepared CCDs-210 exhibited uniform size (< 10 nm), and excellent biocompatibility. Carbonization temperature governed cellular uptake: CCDs-210 entered via active endocytosis, while CCDs-120 used passive diffusion. In uranium-exposed HK-2 cells, CCDs-210 scavenged ROS, stabilized mitochondrial membrane potential, and suppressed the HIF-1α/PPARγ axis, reversing lipid dysregulation and improving cell viability. In vivo, CCDs-210 attenuated renal histopathological damage, restored renal function, and conferred multi-organ protection. These findings establish the HIF-1α/PPARγ axis as a central mediator of uranium nephrotoxicity and demonstrate that CCDs-210, by targeting this axis, effectively mitigate oxidative stress, inflammation, and lipid metabolic disruption. This work provides both a mechanistic foundation and a translatable nanotherapeutic strategy for treating uranium-induced kidney injury.


  • Open Access

    Association of Immunotherapy Duration With Survival in Patients With Unresectable Hepatocellular Carcinoma Achieving Complete Response

    by Yan Chen, Xiao-Wu Zhang, Xielin Feng, Fei Xie, Jinliang Zhang, Xiaoyun Zhang, Xiaoli Yang, Rongce Zhao, Haiqing Wang

    Background: The optimal duration of immune checkpoint inhibitor (ICI) therapy for unresectable hepatocellular carcinoma (HCC) after achieving a clinical complete response (cCR) remains unclear. This study investigated whether fixed 24-week ICI therapy post-cCR provides comparable survival to longer durations.Methods: This multicenter retrospective study included 141 patients with HCC who achieved cCR on first-line ICI-based therapy. Progression-free survival (PFS) and overall survival (OS) were evaluated using a 24-week post-cCR landmark analysis. Multivariable Cox regression models adjusted for clinical covariates were used to assess the association between treatment duration and outcomes.Findings: Among 141 patients (121 men [85.8%]; mean age, 57.9 years), 42 received a fixed 24-week ICI duration and 99 continued beyond 24 weeks. The 24-week group demonstrated significantly shorter median PFS (19.0 vs 39.0 months; P=0.017) and worse OS (P=0.008) compared with the >24-week group. In multivariable analysis, continuation beyond 24 weeks was independently associated with improved PFS (adjusted hazard ratio [HR], 0.53; 95% CI, 0.30-0.93) and OS (adjusted HR, 0.30; 95% CI, 0.12-0.73). For patients experiencing recurrence after discontinuation, ICI rechallenge yielded a 30% objective response rate and a median PFS of 8.0 months.Interpretation: For patients with unresectable HCC achieving cCR, continuing ICI therapy beyond 24 weeks significantly improves PFS and OS compared with a fixed 24-week regimen. Prolonged maintenance therapy appears necessary to sustain optimal clinical benefit.

  • Gastrointestinal Stromal Tumors: Molecular Mechanisms of Drug Resistance and Advances in Therapeutic Strategies

    by Ding Jingnuo, Zhang Huachuan, Zhou Da, Ding Zhi, Chen Yan, Zhao Fazhi

    Gastrointestinal stromal tumors (GISTs), the most common mesenchymal neoplasms of the digestive tract, are primarily driven by gain‐of‐function mutations in the receptor tyrosine kinases KIT or PDGFRA. The introduction of imatinib, a selective tyrosine kinase inhibitor (TKI), revolutionized the management of advanced GIST. However, the emergence of drug resistance remains a major clinical challenge, limiting long‐term efficacy. Resistance mechanisms are multifactorial, predominantly involving secondary mutations in KIT or PDGFRA that impair TKI binding or stabilize the kinase in an active conformation. Beyond genomic alterations, nonmutational adaptive responses—including dysregulation of noncoding RNAs, metabolic reprogramming, epigenetic modifications, and an immunosuppressive tumor microenvironment—significantly contribute to treatment failure. This review comprehensively analyzes these resistance pathways and discusses the evolution of therapeutic strategies toward precision medicine. Current approaches emphasize molecular subtype‐guided first‐line therapy, ctDNA‐driven sequencing of subsequent lines, and the use of novel TKIs (e.g., avapritinib, ripretinib, bezuclastinib) tailored to specific resistance mutations. Furthermore, we explore emerging modalities such as boron neutron capture therapy (BNCT), which offers a kinase‐independent mechanism to target resistant disease, and combination strategies that integrate immunotherapy, epigenetic modulators, and pathway‐specific inhibitors. Advances in liquid biopsy and molecular profiling are enabling real‐time adaptation of therapy, moving GIST management toward a dynamic, personalized paradigm aimed at overcoming resistance and improving patient outcomes.


  • Open Access

    AI and organoid platforms for brain-targeted theranostics

    by Rui Ye, Yupei Zhang, Wan Xu, Li Lai, Zhongwei Zhang, Yan Chen, Shugang Qin

    Developing therapies for complex brain diseases faces significant challenges due to biological complexity and the stringent blood-brain barrier. While nanomedicine holds promise, traditional R&D paradigms suffer from inefficiency. This review introduces an intelligent theranostic paradigm that integrates high-fidelity brain organoid models, high-throughput screening (HTS/HCS), and Artificial Intelligence (AI). In this closed-loop workflow, organoid platforms serve a diagnostic role, generating predictive data on nanomedicine performance. AI then provides therapeutic guidance by processing this data to drive rational drug design, synthesis, and interaction prediction. This AI-driven convergence is poised to significantly accelerate the development of precisely targeted and individualized nanomedicines, offering new hope for breakthroughs in treating brain diseases.


  • Open Access

    Assessment of Survival Benefits Derived from Surgical Resection Subsequent to the Attainment of Complete Response upon Triple Therapy in Hepatocellular Carcinoma: A Multicenter Study

    by Xiaoyun Zhang, Xielin Feng, Liwei Deng, Fei Xie, Yan Chen, Jinliang Zhang, Xuegang Yang, Haiqing Wang

    Introduction: The necessity of surgical resection for hepatocellular carcinoma (HCC) patients who achieve clinical complete response (CR) following triple therapy (transarterial chemoembolization, targeted therapy, and immunotherapy) remains controversial. Thus, this study aimed to compare survival outcomes between surgical resection and nonsurgical management in these patients. Methods: Between January 2018 and March 2024, 127 HCC patients who achieved clinical CR (cCR) following triple therapy were retrospectively included in this study. Patients were stratified into two groups based on whether they underwent surgical resection: the surgical resection group (n = 62) and the nonsurgical resection group (n = 65). Clinical characteristics, imaging findings, pathological results, and long-term outcomes were compared. Propensity score matching (PSM) was performed to mitigate the effect of potential confounders. Results: In the surgical group, 44 of 62 patients (70.9%) achieved pathological CR. The overall postoperative complication rate was 24.2%, with severe complications (grade III–IV) recorded in 8.1% of patients. After PSM, 55 matched pairs were included. One-, two-, and three-year overall survival (OS) rates following cCR were 96.0%, 90.8%, and 90.8% in the surgical group, compared to 91.3%, 85.8%, and 73.1% in the nonsurgical group (p = 0.013). Additionally, one-, two-, and three-year recurrence-free survival (RFS) rates were 81.5%, 74.6%, and 74.6% in the surgical group, compared to 81.1%, 53.5%, and 35.7% in the nonsurgical group (p = 0.020). Finally, multivariate analysis identified surgical resection as an independent prognostic factor for both OS (hazard ratio [HR], 0.266; 95% confidence interval [CI], 0.087–0.817; p = 0.021) and RFS (HR, 0.457; 95% CI, 0.228–0.914; p = 0.027). Conclusion: For HCC patients achieving cCR after triple therapy, surgical resection may confer significant survival benefits and should therefore be considered as an optional treatment method.


  • Open Access

    Neoadjuvant-Based Triple Therapy for Hepatocellular Carcinoma with Type I/II Portal Vein Tumor Thrombosis

    by Guimin Hou, Feng Zhang, Xielin Feng, Yan Chen, Jinliang Zhang, Haiqing Wang

    Hepatectomy could provide better survival benefit for hepatocellular carcinoma (HCC) with type I/II portal vein tumor thrombosis (PVTT). However, the postoperative recurrence remains high. We discussed whether neoadjuvant therapy could reduce HCC recurrence for these patients. One hundred and thirty-eight resectable HCC with type I–II PVTT were retrospectively included. The neoadjuvant therapy regimens included tyrosine kinase inhibitor (TKI), programmed death 1(PD-1) antibodies and transarterial chemoembolization (TACE). Short-term and long-term outcomes were compared. Propensity score matching (PSM) was performed to minimize the influence of potential confounders. Thirty-three patients underwent neoadjuvant therapy and 105 patients underwent surgery alone. In the neoadjuvant group, 7 (21.2%) patients achieved stable disease, 13 (39.4%) achieved partial response and 13 (39.4%) achieved complete response based on the modified Response Evaluation Criteria in Solid Tumors criterion. By PSM, the neoadjuvant therapy resulted in less microvascular invasion (24.1% vs 50.0%, P=0.021), satellite nodule (6.9% vs 24.1%, P=0.036) and less patients with alpha-fetoprotein>20(ng/mL) (37.9% vs 69.0%, P=0.006). The neoadjuvant therapy reduced tumor recurrence and prolonged survival. Multivariate analysis found that neoadjuvant therapy was an independent protective factor for overall survival and recurrence free survival. Neoadjuvant treatment presents a promising treatment option for HCC patients with type I/II PVTT.


  • Open Access

    Strategies and Recent Advances on Improving Efficient Antitumor of Lenvatinib Based on Nanoparticle Delivery System

    by Haiqing Wang, Wentao Bo, Xielin Feng, Jinliang Zhang, Ge Li, Yan Chen

    Lenvatinib (LVN) is a potentially effective multiple-targeted receptor tyrosine kinase inhibitor approved for treating hepatocellular carcinoma, metastatic renal cell carcinoma and thyroid cancer. Nonetheless, poor pharmacokinetic properties including poor water solubility and rapid metabolic, complex tumor microenvironment, and drug resistance have impeded its satisfactory therapeutic efficacy. This article comprehensively reviews the uses of nanotechnology in LVN to improve antitumor effects. With the characteristic of high modifiability and loading capacity of the nano-drug delivery system, an active targeting approach, controllable drug release, and biomimetic strategies have been devised to deliver LVN to target tumors in sequence, compensating for the lack of passive targeting. The existing applications and advances of LVN in improving therapeutic efficacy include improving longer-term efficiency, achieving higher efficiency, combination therapy, tracking and diagnosing application and reducing toxicity. Therefore, using multiple strategies combined with photothermal, photodynamic, and immunoregulatory therapies potentially overcomes multi-drug resistance, regulates unfavorable tumor microenvironment, and yields higher synergistic antitumor effects. In brief, the nano-LVN delivery system has brought light to the war against cancer while at the same time improving the antitumor effect. More intelligent and multifunctional nanoparticles should be investigated and further converted into clinical applications in the future.


  • CRISPR-Mediated Base Editing: Promises and Challenges for a Viable Oncotherapy Strategy

    by Lu Huang, Chao Yang, Yan Chen, Han Deng, Zhi Liao, Hongtao Xiao

    Base editing technology, developed from the CRISPR/Cas9 system, is able to efficiently implement single-base substitutions at specific DNA or RNA sites without generating double-strand breaks with precision and efficiency. Point mutations account for 58% of disease-causing genetic mutations in humans, and single nucleotide variants are an important cause of tumorigenesis, and the advent of base editors offers new hope for the study or treatment of such diseases. Although it has some limitations, base editors have been continuously improved in terms of editing efficiency, specificity, and product purity since their development. In this review, we examine the main base editing technologies and discuss their applications and prospects in tumor research and therapy, as well as elaborate on their mode of delivery.